

March 7, 2022

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director

President and Chief Executive Officer

(Securities Code: 4582)

**SymBio announces initiation of non-clinical study of brincidofovir IV
for brain tumors in collaboration with Brown University, USA**

TOKYO, Japan, March 7, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced the initiation of a non-clinical study in collaboration with Brown University, USA to investigate the anti-tumor efficacy of brincidofovir IV (BCV) against brain tumors associated with cytomegalovirus (CMV) infections.

The study director, Dr. Sean Lawler (Associate Professor at Brown University, Department of Pathology and Laboratory Medicine), commented that he is hopeful that the findings from the study will lead to provide evidence for new treatments for brain tumors associated with viral infections.

Statement from Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio: "Although many new drugs are being developed for the treatment of brain tumors, none of them have a mechanism of action for cytomegalovirus infection, which accounts for about half of brain tumors. Only BCV have mechanism of action which combines antiviral and anti-cancer activities, and we are pursuing the development of new treatments in therapeutic areas where no effective treatments have been established."

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 31, 2022.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Anti-viral Drug Brincidofovir

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV. SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox).

Introduction to Dr. Sean Lawler

Dr. Sean Lawler's Brown University is one of the Ivy League schools located in Providence, Rhode Island, USA. Brown is a leading research university where rigorous scholarship, complex problem-solving and service to the public good are defined by intense collaboration, intellectual discovery and working in ways that transcend traditional boundaries. To date, Dr. Lawler has led the work of bridging non-clinical and clinical studies to consistently develop therapeutic agents for brain tumors, and has remained a great deal of experience in animal models to demonstrate in recent years that viral infections have critical roles in the malignant transformation of brain tumors.

<https://pubmed.ncbi.nlm.nih.gov/30855281/>

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Mr. Fuminori Yoshida).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.